Documents
■Keynote lecture
■RA Session
- RA-3. Importance of predictability & transparency to facilitate reliance scheme
- RA-4. Predictability and Transparency to facilitate Reliance Schemes Industry perspective & Insights from APAC survey
- RA-6. Best practice for predictability & transparency to facilitate reliance
- RA-7. Best Practice for Predictability & Transparency to Facilitate Reliance Scheme in Thailand
- RA-8. Asia Office’s activity to support to facilitate reliance scheme
■DA Session
- DA-1. Opeing
- DA-2. Accelerating Microbiome-Based Drug Discovery in Asia The Power of Public-Private Partnerships
- DA-3. Identification of Beneficial Bacteria in the Japanese Population and its Application to Microbiome Medicines
- DA-4. Regulatory Perspective on Quality Aspects for Microbiome Medicines in Japan
■e-labeling Session
- e-labeling Session-1. “e-labeling Session” Accelerate e-labeling initiatives, interoperability across digital health platforms, as part of health data ecosystem for patients
- e-labeling Session-3. FHIR ePI and the Future of Electronic Labeling and Digital Health
- e-labeling Session-4. e-labeling Progression - Thailand
- e-labeling Session-5. The Future of Pharmaceutical Labelling Updates on Malaysia's e-Labelling Initiative
- e-labeling Session-6. Advancing E-Labeling in Taiwan Implementation Journey and Future Plans
■MQS Session
■aUHC Session
- aUHC-3. New Drug Expenditure by Therapeutic Area in South Korea International Comparison and Policy Implications
- aUHC-4. Utilizing health technology assessment (HTA) to support health reimbursement decisions in Thailand
- aUHC-5. The role of commercial health insurance within the Singapore health financing system
- aUHC-6. Taiwan's Cancer Drugs Fund (TCDF) Enhancing Access to Innovative Cancer Medicines
